GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Betta Pharmaceuticals Co Ltd (SZSE:300558) » Definitions » Net Income Including Noncontrolling Interests

Betta Pharmaceuticals Co (SZSE:300558) Net Income Including Noncontrolling Interests : ¥379 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Betta Pharmaceuticals Co Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Betta Pharmaceuticals Co's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2024 was ¥94 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 was ¥379 Mil.


Betta Pharmaceuticals Co Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Betta Pharmaceuticals Co's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Betta Pharmaceuticals Co Net Income Including Noncontrolling Interests Chart

Betta Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only 225.84 601.09 379.56 124.76 333.62

Betta Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.94 93.64 152.55 39.49 93.79

Betta Pharmaceuticals Co Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥379 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Betta Pharmaceuticals Co Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Betta Pharmaceuticals Co's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


Betta Pharmaceuticals Co (SZSE:300558) Business Description

Industry
Traded in Other Exchanges
N/A
Address
No.355, Xingzhong Road, Yuhang Economic and Technological Development Zone, Zhejiang Province, Hangzhou, CHN
Betta Pharmaceuticals Co Ltd is a hi-tech pharmaceutical enterprise focuses on research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates through China.
Executives
Wang Jia Bing Directors, executives
Ding Lie Ming Directors, executives
Cai Wan Yu Executives

Betta Pharmaceuticals Co (SZSE:300558) Headlines

No Headlines